1. All registries/studies are anti-TNF focused, excepting ORA (abatacept), AIR (rituximab), and RABBIT (anti-TNFs and anakinra). AIR = Autoimmunity and Rituximab; ARTIS = Swedish Biologics Register; BSRBR = British Society for Rheumatology Biologics Register; CORRONA = Consortium of Rheumatology Researchers of North America; LORHEN = Lombardy Rheumatology Network; NOR-DMARD = Norwegian DMARD register; ORA = Orencia and RA; RABBIT = Rheumatoid Arthritis—Observation of Biologic Therapy; US = United States. ORA 5 35% ARTIS 4 30% NOR- DMARD 1 33% LORHEN 8 12% RABBIT 3 34% AIR 5 33% BSRBR 2 32% US health care insurance claims databases 6 30% CORRONA 7 30% Approximately 30% of Patients With RA Are Treated With Biologic Monotherapy: Biologics Registries and US Claims Database 1. Heiberg MS, et al. Arthritis Rheum. 2008;59:234-240. 2. Soliman MM, et al. Ann Rheum Dis. 2011;70:583-589. 3. Listing J, et al. Arthritis Res Ther. 2006;8:R66. 4. Askling J, et al. Ann Rheum Dis. 2007;66:1339-1344. 5. Mariette X, et al. Rheumatology. 2011;50:222-229. 6. Yazici Y, et al. Bull NYU Hosp Jt Dis. 2008;66:77-85. 7. Lee SJ, et al. J Rheumatol. 2009;36:1611-1617. 8. Sarzi-Puttini P, et al. Reumatismo. 2008;60:290-295.

2. Cohort B: bleeding endpoints (treated bleeds) *Other bleeds occurring in joint or muscle represent subcutaneous haematomas; most frequent location classified as ‘other’ was the mouth. Joint locations, including knee, ankle or elbow, were also reported under ‘other’ when the bleed was around the joint.Oldenburg J, et al. ASH 2017; poster presentation 1089 Prophylactic, n = 14 Total: 101 Joint: 45.5% Muscle: 18.8% Other organs/tissue: 35.6% Episodic, n = 10 Total: 121 Joint: 55.4% Muscle: 13.2% Other* organs/tissue: 31.4% 26% 3% 6% 3% 17% 14% 4% 13% 5% 10% Total treated bleeds: 222 N = 24 The most frequent types of bleeds were joint bleeds, primarily occurring in the elbow All (N = 24)